ClinicalTrialsFinder
RecruitingPhase 4NCT07166939

45th Multicenter Airway Research Collaboration

A Phase 4, Multicenter, Cluster Randomized, Open-label, Intervention Versus Usual Care, Controlled Study on the Effect of Emergency Department Initiation of Airsupra on Asthma Outcomes

Sponsor

Massachusetts General Hospital

Enrollment

1,860 participants

Start Date

Nov 7, 2025

Study Type

INTERVENTIONAL

Conditions

AsthmaAsthma AcuteAsthma ExacerbationAsthma Control Level

Summary

The study is a randomized controlled trial on the effect of emergency department initiation of Airsupra on acute asthma "recurrence" at 3 months and other related outcomes (acute asthma relapse, asthma control).

Eligibility

Min Age: 18 YearsMax Age: 54 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Airsupra for people with asthma, asthma acute, and other related conditions. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years to 54 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGAirsupra

1 dose (2 inhalations) PRN, with maximum of 6 doses (12 inhalations) in a 24-hour period

Locations(1)

MetroHealth

Cleveland, Ohio, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07166939

Related Trials

NHALES (Natural History of Asthma With Longitudinal Environmental Sampling)

NCT023278971 location

Personalized Environment and Genes Study

NCT003412372 locations

Role of Genetic Factors in the Development of Lung Disease

NCT000015322 locations

Children's Health, Respiratory Inflammation and Short-term Air Pollution

NCT074310211 location

Study of Lunsekimig (SAR443765) Compared With Placebo in Adults With High-risk Asthma

NCT06676319229 locations